Adenoid cystic carcinoma of the salivary gland — one of the most distinctive and clinically challenging of all salivary gland malignancies, accounting for approximately 10–15% of salivary gland carcinomas overall and the most common carcinoma of the submandibular gland and minor salivary glands of the palate, tongue, floor of mouth, and sinonasal tract, arising most frequently in the minor salivary glands (approximately 50–60% of cases), followed by the parotid gland (20–25%), and the submandibular gland (15–20%), classified by histologic growth pattern into three subtypes that directly predict clinical behavior (tubular — glands and trabeculae with the most favorable prognosis and best five-year survival; cribriform — the classic "Swiss cheese" or cylindromatous pattern with pseudocystic spaces containing basophilic mucoid material, the most common pattern; and solid — sheets of basaloid cells without glandular differentiation, the most aggressive pattern associated with the shortest survival and highest rate of distant metastasis; WHO 2022 classification recommends reporting the predominant pattern and the percentage of solid component — ≥30% solid correlates with adverse outcome), characterized pathologically by dual cell populations of luminal ductal cells and abluminal myoepithelial cells, characteristic perineural invasion (a near-universal feature — present in 60–80% of cases, with skip lesions along named cranial nerve branches extending from the primary site to the skull base — particularly branches of the facial nerve CN VII in parotid primaries, the lingual nerve and inferior alveolar nerve for submandibular and minor salivary gland primaries, and the palatine nerves for palatal primaries), with the defining molecular alteration being the MYB::NFIB fusion — most commonly t(6;9)(q22-23;p23-24) — present in approximately 30–85% of adenoid cystic carcinomas depending on detection method (RNA sequencing is more sensitive than FISH; NGS comprehensive panels increasingly standard), and alternatively MYBL1::NFIB (5–10%) or other MYBL1 rearrangements and MYB amplification in MYB-NFIB fusion-negative cases, with additional recurrent alterations including NOTCH1 activating mutations (particularly in solid-pattern/high-grade transformation adenoid cystic carcinoma — associated with aggressive behavior and potentially targetable with gamma-secretase inhibitors), CDKN2A deletion, TP53 mutation (associated with high-grade transformation), and KIT expression (present in 70–90% without activating KIT mutations — imatinib trials historically unremarkable), with treatment for localized disease being surgical resection (parotidectomy — total or radical with facial nerve dissection and potential sacrifice for perineural involvement; submandibular gland excision; wide excision for minor salivary gland sites with clear margins — notoriously difficult given perineural spread beyond clinical and imaging margins) followed by adjuvant radiotherapy (standard of care for virtually all resected adenoid cystic carcinomas given the perineural spread and margin positivity patterns — IMRT 60–66 Gy with extended field to cover the involved cranial nerve course to the skull base; proton beam therapy and neutron capture therapy offering superior dosimetry for skull base perineural extension or unresectable disease), and with systemic therapy for recurrent or metastatic adenoid cystic carcinoma (most commonly pulmonary metastases, which can be indolent over years — lenvatinib multikinase inhibitor showing modest activity; axitinib; larotrectinib for NTRK fusions as rare off-target rearrangements; olaparib for BRCA-mutated cases; NOTCH1 pathway inhibitors in clinical trials; AL101 gamma-secretase inhibitor for NOTCH1-activated adenoid cystic carcinoma in trials) — making integrated head and neck surgical oncology, radiation oncology, surgical pathology, neuroradiology (for perineural spread mapping), and molecular profiling platforms essential.
Adenoid cystic carcinoma technology platforms — whether supporting the surgical pathology programs performing adenoid cystic carcinoma histologic pattern classification (tubular, cribriform, solid percentage; Ki-67 proliferation index; perineural invasion — named nerve branch involvement documentation; lymphovascular invasion; MYB/MYBL1 FISH or RNA fusion sequencing; NOTCH1 mutation NGS; KIT IHC), the neuroradiology programs performing MRI skull base and perineural spread mapping (fat-suppressed T1 post-gadolinium sequences tracing perineural tumor along V3, V2, CN VII branches from the primary site to the skull base — a critical preoperative and radiation field planning input), the head and neck surgery programs performing parotidectomy (total parotidectomy — standard for parotid adenoid cystic carcinoma given multilobar involvement; facial nerve dissection — identification and tracing of all five branches for perineural tumor tracking; planned facial nerve sacrifice with cable graft reconstruction for perineural invasion of the main trunk), the radiation oncology programs delivering extended-field IMRT (primary site plus involved cranial nerve course to the skull base — extended coverage to Meckel's cave, gasserian ganglion, or the geniculate ganglion depending on primary site and perineural spread pattern), the medical oncology programs managing systemic therapy for recurrent or metastatic adenoid cystic carcinoma (lenvatinib, axitinib, larotrectinib, olaparib, NOTCH1 pathway inhibitors in trials), the molecular profiling platforms performing MYB/MYBL1 FISH, RNA fusion sequencing for NFIB rearrangements, NOTCH1 mutation NGS, and comprehensive molecular profiling, and the multidisciplinary head and neck tumor board programs — must maintain the availability and performance standards that adenoid cystic carcinoma's perineural spread-driven surgical and radiotherapy complexity, extended field radiation to the skull base, molecular profiling for NOTCH1 activation and NTRK rearrangements, and indolent long-term metastatic disease surveillance demand. This guide explains why adenoid cystic carcinoma tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the perineural spread mapping, extended-field radiotherapy, molecular profiling, and long-term surveillance of modern adenoid cystic carcinoma care.
Why Adenoid Cystic Carcinoma Tech Platforms Require Specialized Monitoring Attention
Adenoid cystic carcinoma management is defined by four platform-dependent complexities: the surgical pathology platform providing histologic pattern and perineural invasion extent that determine adjuvant radiation field; the neuroradiology platform providing perineural spread mapping to the skull base that defines surgical and radiation treatment extent; the radiation oncology platform delivering extended-field IMRT covering the cranial nerve course to the skull base; and the long-term systemic therapy and surveillance platform managing the indolent pulmonary metastatic disease pattern.
Surgical pathology platforms drive histologic pattern and perineural invasion mapping that determine radiation field extent. Tubular-predominant (>30% tubular — favorable), cribriform-predominant (most common), and solid-predominant (≥30% solid — aggressive, highest distant metastasis rate) are the pattern classifications that predict outcome. Named nerve branch perineural invasion — which facial nerve branch, which division of the trigeminal nerve, which submandibular nerve branch — determines the radiation oncology extended-field planning from the primary site along the named nerve to the skull base. MYB::NFIB fusion confirmation and NOTCH1 mutation status further refine prognosis and emerging targeted therapy eligibility. Monitor surgical pathology platforms during diagnostic hours.
Neuroradiology platforms define perineural spread extent and radiation field planning. Fat-suppressed T1 post-gadolinium MRI skull base sequences tracing perineural enhancement from the parotid bed along CN VII branches to the stylomastoid foramen, geniculate ganglion, and temporal bone, or along V3/V2 from minor salivary gland primaries to Meckel's cave — the perineural spread map that defines whether the radiation oncology CTV encompasses the temporal bone and skull base, whether the surgical plan includes skull base dissection, and whether the neurosurgical team must participate in planned facial nerve reconstruction. Monitor neuroradiology platforms during preoperative diagnostic and radiation planning periods.
Extended-field IMRT platforms cover the primary site plus cranial nerve course to the skull base. Standard adjuvant IMRT for adenoid cystic carcinoma encompasses the primary tumor bed plus the entire course of the involved cranial nerve from the primary site to the skull base — a technically complex extended radiation field with critical OAR constraints (cochleae, brainstem, temporal lobes, optic chiasm/nerves for skull base-adjacent fields) that differs substantially from other head and neck IMRT configurations. Monitor radiation oncology platforms during treatment delivery hours.
Systemic therapy and surveillance platforms manage the indolent pulmonary metastatic pattern. Adenoid cystic carcinoma's characteristic pattern of pulmonary metastases — which may be present for years or decades with slow progression and limited symptoms — requires longitudinal CT chest surveillance records, molecular profiling to identify actionable alterations (NOTCH1 for gamma-secretase inhibitors in trials; NTRK fusions for larotrectinib), and systemic therapy records (lenvatinib, axitinib) for progressive symptomatic metastatic disease. Monitor systemic therapy and surveillance platforms continuously.
What to Monitor on an Adenoid Cystic Carcinoma Tech Platform
Surgical Pathology Platforms
Monitor adenoid cystic carcinoma surgical pathology records (histologic pattern — tubular percentage, cribriform percentage, solid percentage; Ki-67 proliferative index; T-stage — T1: ≤2 cm; T2: >2 cm, ≤4 cm; T3: >4 cm or extraparenchymal extension; T4a: skin, mandible, ear canal, facial nerve; T4b: skull base, pterygoid plates, carotid encasement; margin status — millimeters from inked margin; perineural invasion — named nerve branch documentation: main trunk facial nerve vs. branch perineural invasion; lingual nerve; inferior alveolar nerve; palatine nerve branches; lymphovascular invasion; lymph node status), MYB/MYBL1 FISH records (MYB::NFIB fusion; MYBL1::NFIB fusion; MYB amplification in fusion-negative cases), RNA fusion sequencing records (comprehensive fusion detection for MYB/MYBL1 rearrangements; NTRK1/2/3 fusion exclusion), IHC records (MYB IHC overexpression as surrogate; KIT IHC — usually positive, without activating mutation; CD117; SOX10; SMA/calponin myoepithelial markers), NOTCH1 mutation NGS records (NOTCH1 activating mutations associated with solid pattern/high-grade transformation and NOTCH pathway inhibitor trial eligibility), and high-grade transformation assessment records (increased mitotic activity, necrosis, nuclear pleomorphism, loss of dual-cell architecture). Alert immediately — surgical pathology platform failures when the head and neck surgeon and radiation oncologist awaiting the perineural invasion documentation need the named nerve branch perineural involvement extent to define the surgical dissection plane and the extended radiation field CTV from the primary site to the skull base.
Neuroradiology Platforms
Monitor MRI skull base records for perineural spread mapping (fat-suppressed T1 post-gadolinium sequences at 3mm or 1.5mm slice thickness through the primary site, parotid bed, stylomastoid foramen, facial nerve canal in the temporal bone, geniculate ganglion, and internal auditory canal for parotid adenoid cystic carcinoma; V3/inferior alveolar nerve tracking from mandibular foramen to foramen ovale and Meckel's cave for submandibular/floor-of-mouth primaries; V2/infraorbital nerve tracking to foramen rotundum for palatal/maxillary primaries; orbital CT/MRI for orbital perineural involvement in maxillary sinus primaries), radiation treatment planning MRI fusion records (MRI-CT fusion for IMRT CTV delineation), and post-treatment surveillance MRI records for local recurrence detection (perineural recurrence often detectable only on MRI with fat suppression — not visible on CT). Alert immediately — neuroradiology platform failures during preoperative skull base MRI perineural spread mapping prevent the head and neck surgeon from accessing the imaging that defines whether the surgical plan includes skull base dissection, lateral temporal bone resection, or orbital exenteration for perineural extension beyond the primary compartment.
Extended-Field Radiation Oncology Platforms
Monitor IMRT simulation and treatment planning records for adenoid cystic carcinoma (CT simulation with MRI fusion; GTV delineation — primary tumor bed, positive nodes; CTV high-risk — primary site plus involved cranial nerve course to skull base; CTV intermediate-risk — elective neck levels; dose prescription — 66 Gy/33 fx high-risk CTV, 60 Gy/30 fx intermediate-risk; OAR constraints — cochleae mean <20 Gy; brainstem <54 Gy; temporal lobes mean <45 Gy for extended skull base fields; optic chiasm <54 Gy; contralateral parotid mean <24 Gy; spinal cord <45 Gy; mandible D2% <70 Gy), daily IMRT delivery records (CBCT image guidance; beam delivery MUs; setup correction records), proton beam therapy planning and delivery records for skull base perineural extension cases, and radiotherapy toxicity monitoring records. Alert immediately — radiation oncology platform failures during extended-field IMRT covering the skull base prevent the radiation therapist from accessing the prior fraction delivery records and CBCT image guidance verification needed before proceeding with the current fraction delivering dose adjacent to the brainstem and cochleae.
Systemic Therapy Platforms
Monitor systemic therapy records for recurrent or metastatic adenoid cystic carcinoma (lenvatinib — multikinase inhibitor for progressive metastatic disease; axitinib — VEGFR-targeted therapy; larotrectinib/entrectinib for rare NTRK fusion-positive adenoid cystic carcinoma; olaparib for BRCA-mutated cases; AL101 or other gamma-secretase inhibitors for NOTCH1-activated adenoid cystic carcinoma in clinical trials; cisplatin-based combinations for rapidly progressive solid-pattern disease), dose modification records, toxicity monitoring (lenvatinib: hypertension, proteinuria, hepatotoxicity, fatigue; axitinib: hypertension, fatigue, dysphonia), and response assessment CT records for pulmonary metastases (indolent pulmonary nodule surveillance vs. progressive disease determination). Alert immediately — systemic therapy platform failures when a patient with progressive pulmonary metastatic adenoid cystic carcinoma on lenvatinib requires urgent access to the prior dose modification records documenting a Grade 2 hypertension event at cycle 3 and the lenvatinib dose reduction to 14 mg from 18 mg.
Molecular Profiling Platforms
Monitor MYB/MYBL1 FISH and RNA fusion sequencing records, NOTCH1 mutation NGS records (NOTCH1 activating mutations for gamma-secretase inhibitor trial eligibility), comprehensive NGS records (CDKN2A, TP53, PIK3CA, NTRK fusions, RET fusions, FGFR alterations, TMB, MSI, PD-L1 TPS), and germline testing records for rare hereditary cases. Alert immediately — molecular profiling platform failures prevent the medical oncologist from accessing NOTCH1 mutation results determining gamma-secretase inhibitor clinical trial eligibility for a patient with progressive solid-pattern adenoid cystic carcinoma with multiple pulmonary metastases.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Adenoid cystic carcinoma programs coordinate across surgical pathology (MYB FISH, RNA fusion, NOTCH1 NGS, dual-cell IHC), neuroradiology (skull base MRI perineural spread mapping), head and neck surgery (parotidectomy with facial nerve sacrifice and reconstruction planning), neurosurgery (skull base extension cases), radiation oncology (extended-field IMRT to skull base), medical oncology (lenvatinib, axitinib, trial agents), molecular oncology, reconstructive surgery, speech-language pathology, and multidisciplinary tumor board.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, surgical pathology reporting systems, neuroradiology PACS and MRI report systems, head and neck surgery operative platforms, radiation therapy delivery systems, and systemic therapy administration platforms. Certificate errors disrupt the perineural spread mapping report access, operative record retrieval, extended-field IMRT delivery verification, and systemic therapy administration records.
HIPAA and Oncology Data Privacy Considerations
Adenoid cystic carcinoma technology platforms handle sensitive PHI including MRI skull base perineural spread imaging records (detailed head and neck imaging with soft tissue and nerve anatomy disclosing sensitive personal health information), planned facial nerve sacrifice records (facial paralysis is a visible, socially significant disability with employment and self-image implications), long-term pulmonary metastasis surveillance records spanning years to decades of follow-up (sensitive longitudinal oncology data requiring extended retention), NOTCH1 mutation and MYB molecular results (with clinical trial eligibility implications), and indolent metastatic disease records (the disclosure that a patient has stable pulmonary metastases can affect life insurance, employment disability evaluations, and caregiver planning across decades).
Alerting Strategy for Adenoid Cystic Carcinoma Tech Platforms
Immediate alerting during surgical pathology reporting: Histologic pattern, perineural invasion extent, MYB/MYBL1 FISH, RNA fusion sequencing, and NOTCH1 mutation platforms.
Immediate alerting during skull base MRI and perineural spread mapping: Neuroradiology PACS and reporting platforms — the perineural spread map drives surgical and radiation field extent.
Immediate alerting during extended-field IMRT delivery: Radiation therapy delivery platforms with daily CBCT image guidance, OAR dose tracking, and skull base extended-field fraction delivery verification.
Immediate alerting during systemic therapy: Lenvatinib, axitinib, and clinical trial agent administration platforms for recurrent/metastatic disease.
Immediate alerting during molecular profiling: MYB, NOTCH1, and NGS platforms determining prognosis and clinical trial eligibility.
Sustained-failure alert (10–15 minutes): Facial nerve rehabilitation, speech-language pathology, pulmonary metastasis surveillance, and multidisciplinary tumor board platforms.
30-day advance warning: SSL certificates across all domains.
Status Page for Adenoid Cystic Carcinoma Care Team Communication
A real-time status page gives surgical pathologists confirming MYB::NFIB fusion and perineural invasion extent, neuroradiologists providing skull base perineural spread mapping reports, head and neck surgeons accessing facial nerve monitoring and skull base operative records, radiation oncologists verifying extended-field IMRT delivery and OAR dose tracking, medical oncologists reviewing NOTCH1/NGS molecular results for clinical trial eligibility, and multidisciplinary head and neck tumor board members coordinating the complex multi-specialty care immediate platform visibility without requiring IT support contact. During an extended-field IMRT skull base course when the electronic health record is unavailable, a status page enables immediate downtime protocol activation so the radiation therapy team can document CBCT image guidance positional corrections and daily MU delivery via paper-based downtime procedures.
Include the status page URL in adenoid cystic carcinoma pathology downtime procedures, neuroradiology PACS downtime protocols, head and neck surgery operative downtime procedures, extended-field IMRT delivery downtime protocols, and systemic therapy administration downtime procedures.
Vigilmon Setup for Adenoid Cystic Carcinoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Surgical pathology platform / histologic pattern, MYB FISH, NOTCH1 | 1 min | Slack + PagerDuty (diagnostic hours) | | Neuroradiology platform / skull base MRI perineural spread mapping | 1 min | Slack + PagerDuty (diagnostic hours) | | Head and neck surgery platform / parotidectomy, facial nerve, skull base | 1 min | Slack + PagerDuty (operative hours) | | Extended-field IMRT platform / skull base delivery and CBCT image guidance | 1 min | Slack + PagerDuty (treatment hours) | | Proton beam therapy platform / skull base perineural extension cases | 1 min | Slack + PagerDuty (treatment hours) | | Lenvatinib/axitinib systemic therapy platform | 1 min | Slack + PagerDuty (clinical hours) | | NOTCH1 pathway inhibitor trial platform / gamma-secretase inhibitors | 1 min | Slack + PagerDuty (clinical hours) | | NTRK-targeted therapy platform / larotrectinib for NTRK fusion-positive cases | 1 min | Slack + PagerDuty (clinical hours) | | Molecular profiling platform / MYB FISH, RNA fusion, NOTCH1 NGS | 1 min | Slack + PagerDuty (diagnostic hours) | | Pulmonary metastasis surveillance platform / CT chest longitudinal tracking | 2 min | Slack (business hours) | | Facial nerve rehabilitation platform / House-Brackmann serial assessment | 2 min | Slack (clinical hours) | | Speech-language pathology platform / xerostomia, dysphagia monitoring | 2 min | Slack (clinical hours) | | Multidisciplinary head and neck tumor board | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure surgical pathology platforms with immediate alerting — histologic pattern (solid percentage), perineural invasion, MYB FISH, NOTCH1 mutation determine radiation field extent and prognosis
- Add neuroradiology platforms with immediate alerting — skull base MRI perineural spread mapping is the critical input for surgical extent and extended-field radiation planning
- Configure extended-field IMRT platforms with immediate alerting including skull base daily fraction delivery records, CBCT image guidance verification, and OAR dose tracking
- Add proton beam therapy platforms for skull base perineural extension or unresectable disease
- Configure lenvatinib/axitinib and clinical trial agent platforms for progressive metastatic disease
- Add molecular profiling platforms — MYB/MYBL1 FISH, RNA fusion, NOTCH1 NGS, comprehensive NGS for trial eligibility
- Configure pulmonary metastasis surveillance platforms for longitudinal indolent pulmonary nodule tracking
- Add facial nerve rehabilitation and speech-language pathology platforms for quality-of-life monitoring
- Enable SSL certificate monitoring across all clinical, neuroradiology, pathology, operative, RT delivery, molecular, and tumor board domains
Conclusion
Adenoid cystic carcinoma technology platforms are embedded in clinical decisions where surgical pathology platform availability for histologic pattern classification and perineural invasion documentation — where the surgical pathologist must quantify the solid pattern percentage (distinguishing cribriform-predominant [most common, intermediate prognosis] from solid-predominant [≥30% solid — the highest-risk histologic subtype with five-year survival rates substantially lower than tubular or cribriform adenoid cystic carcinoma, and the subtype with highest rates of local recurrence, lymph node metastasis, and distant metastasis to lung, liver, and bone], document all named nerve branches with perineural tumor (the facial nerve main trunk in parotid primaries — is the tumor tracking toward the stylomastoid foramen and temporal bone, requiring radiation field extension to the skull base and geniculate ganglion?; the lingual nerve in submandibular primaries — is the tumor tracking toward foramen ovale and Meckel's cave, requiring extended-field radiation through the skull base?; the palatine nerve in palatal primaries — is the tumor tracking toward the greater palatine canal and pterygopalatine fossa?), confirm MYB::NFIB fusion by FISH or RNA sequencing, and report NOTCH1 activation status for emerging gamma-secretase inhibitor trial eligibility — before the radiation oncologist can design the extended-field CTV that encompasses the entire perineural spread course from the primary site to the skull base, a field design that requires the surgical pathology records of named nerve perineural involvement matched against the neuroradiology MRI perineural spread mapping to define the superior limit of the extended radiation field (stylomastoid foramen vs. geniculate ganglion vs. internal auditory canal for facial nerve; foramen ovale vs. Meckel's cave for V3; foramen rotundum vs. cavernous sinus for V2) — cannot be interrupted by platform outage when the perineural invasion documentation and the skull base MRI perineural enhancement extent together define the radiation field that must cover the entire tumor-involved nerve length to achieve adequate local control; where neuroradiology platform availability for skull base MRI perineural spread imaging at the preoperative planning stage provides the precise anatomical map of perineural enhancement tracing from the parotid bed along the facial nerve branches through the stylomastoid foramen, along the mastoid segment, to the geniculate ganglion — a perineural spread pattern that converts the surgical plan from a total parotidectomy with facial nerve preservation to a total parotidectomy with planned facial nerve sacrifice at the stylomastoid foramen and immediate cable graft reconstruction, and converts the radiation CTV from a standard parotid bed field to an extended field encompassing the temporal bone from the stylomastoid foramen to the internal auditory canal — a field extension that changes dose constraints to the ipsilateral cochlea (now within the extended CTV requiring boosted dose) and mandates the cochlear sparing and temporal lobe dose constraint adjustments that can only be implemented when the neuroradiology perineural spread map is available to the radiation oncology treatment planning team; and where extended-field IMRT platform availability during fraction 20 of a 33-fraction adenoid cystic carcinoma course treating the primary parotid site plus the perineural extension field to the temporal bone skull base — where the radiation therapist must access the prior fraction delivery records confirming that cumulative dose to the high-risk skull base CTV is tracking at planned 95% isodose coverage, the ipsilateral cochlea mean dose is tracking below the 20 Gy constraint (critical for hearing preservation in a patient whose contralateral ear may be within the radiation field for bilateral neck coverage), and the CBCT image guidance positional shift records from prior fractions confirm consistent positioning at the skull base level — cannot be interrupted by platform outage when the cumulative dose records to the skull base extended field are the clinical safety chain preventing overdose to the brainstem, cochleae, and temporal lobes.
Uptime monitoring gives adenoid cystic carcinoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to surgical pathology programs confirming MYB::NFIB fusion and mapping perineural invasion by named nerve branch, neuroradiology programs mapping skull base perineural enhancement with fat-suppressed T1 gadolinium-enhanced MRI, head and neck surgery programs performing total parotidectomy with planned facial nerve sacrifice and cable graft reconstruction, radiation oncology programs delivering technically complex extended-field IMRT covering the cranial nerve course to the skull base with OAR constraints for cochleae, brainstem, and temporal lobes, medical oncology programs managing lenvatinib, axitinib, and NOTCH1 pathway inhibitor trials for progressive pulmonary metastatic disease, molecular oncology programs performing MYB FISH, RNA fusion sequencing, and NOTCH1 NGS for trial eligibility, long-term surveillance programs tracking indolent pulmonary nodule evolution over years to decades, multidisciplinary head and neck tumor board programs coordinating surgical, radiation, and systemic therapy sequencing, and compliance auditors that platform operational reliability matches the perineural invasion precision, skull base imaging accuracy, extended-field radiation delivery verification, NOTCH1 molecular profiling, and multi-decade surveillance continuity that modern adenoid cystic carcinoma care demands.
Start monitoring your adenoid cystic carcinoma salivary gland care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #adenoidcysticcarcinoma #salivaryglandcancer #parotidcancer #MYB #NFIB #MYBLFIB #NOTCH1 #perineuralspread #skullbase #parotidectomy #facialnerve #IMRT #protontherapy #adjuvantradiotherapy #lenvatinib #axitinib #larotrectinib #NTRK #gammasecrease #pulmonarymetastasis #headandneckcancer #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre